Home › 3BBLACKBIO › Filing
🔔 Get instant alerts when 3BBLACKBIO files quarterly results on BSE Start free trial →
3B Blackbio Dx Limited (3BBLACKBIO)

Disclosure under Regulation 30 of SEBI (LODR)Regulations, 2015

Filed: 18 Nov 2026, 17:25 IST Exchange: BSE Category: Merger/Acquisition — Acquisition of Bilex SRL
3B BlackBio Dx Ltd's subsidiary Coris Bioconcept SRL acquired 100% shares of Bilex SRL, owner of Coris's office and manufacturing building in Belgium, on Nov 18, 2026. - Acquisition cost: €274,817 plus payment of €1.32M unsecured loan and assumption of €2.11M long-term loans. - Transition from tenant to owner-occupier, eliminating intercompany rental payments. - Expected immediate net annual savings of €140,000 before depreciation. - Facility includes advanced labs, solar panels, and eco-friendly features. - Acquisition aligns with long-term cost optimization and infrastructure security for global diagnostics.
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 3BBLACKBIO — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add 3BBLACKBIO to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on 3B Blackbio Dx Limited

Important. The summary above is generated automatically from 3B Blackbio Dx Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.